摘要
糖尿病病人的胰岛素治疗往往是长期的。胰岛素所致的低血糖、体重增加、肿瘤风险是选择胰岛素治疗方案时需要考虑的问题。德谷胰岛素作为基础胰岛素,是最新型的一种超长效胰岛素类似物,它以平稳缓慢释放、维持作用时间长、吸收变异性小、低血糖发生率低、用药灵活、有利于控制高血糖和降低夜间低血糖的发生等独特优势,为糖尿病病人的胰岛素治疗提供了一种新选择。
Patients with diabetes usually require long-term insulin medication. Hypoglycemia, weight gain and cancer risk induced by insulin medication are the factors that should be considered in the selection of insulin medication protocols. Being a basal insulin, insulin degludec is a brand-new ultra-long-acting insulin analogue. With unique advantages of stable and slow re- lease, sustained acting time, minor absorption variability, low incidence of hypoglycemia, flexible dosage, good control of high blood glucose and low incidence of nocturnal hypoglycemia, insulin degludec offers a new choice for insulin therapy of diabetes patients.
出处
《药学服务与研究》
CAS
CSCD
2013年第1期6-8,共3页
Pharmaceutical Care and Research
